RVL Pharmaceuticals plc reaffirmed sales guidance for the fourth quarter of 2022. For the period, the company expects the net sales of UPNEEQ to be $12 to $14 million, representing sequential growth of 20% to 40% compared to the third quarter of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | -99.97% |
04-12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
03-21 | North American Morning Briefing : Investors -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-99.97% | 11.14K | |
+0.62% | 91.72B | |
0.00% | 39.44B | |
-10.35% | 34.47B | |
+64.64% | 26.7B | |
-16.15% | 15.13B | |
-6.98% | 13.27B | |
-11.77% | 11.74B | |
-49.19% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- RVLP.Q Stock
- News RVL Pharmaceuticals plc
- RVL Pharmaceuticals plc Reaffirms Sales Guidance for the Fourth Quarter of 2022